secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2026-09-29T21:19:22+00:00
Accession:  0001193125-26-407823
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tectonic reports favorable TX2100 Phase 1a safety results and FDA Fast Track for HHT
--------------------------------------------------------------------------------

- TX2100 Phase 1a single ascending doses were generally safe and well-tolerated across all six planned cohorts; no deaths, SAEs, or severe TEAEs at any dose.
- FDA granted TX2100 Fast Track designation for hereditary hemorrhagic telangiectasia (HHT) and cleared the IND for a U.S. Phase 1b trial in HHT patients.
- Tectonic plans an open-label Phase 1b trial in hematologic-support dependent HHT by year-end 2026 and a placebo-controlled Phase 2 in moderate-to-severe HHT in early 2027.
- The Phase 1a trial enrolled 48 healthy adults ages 18-55 across six cohorts of eight, randomized 3:1 to TX2100 or placebo; Part B multiple-dose enrollment is complete.
- PK results showed target-mediated drug disposition at low concentrations, supporting once weekly or every other week subcutaneous dosing; detailed data to be presented Oct. 12-16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526407823/0001193125-26-407823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526407823/d20857d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-407823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer